Mydocalm coated pills 150mg N30
Condition: New product
999 Items
Rating:
Be the first to write a review!
More info
Active ingredients
Tolperisone
Release form
Pills
Composition
Active ingredient: Tolperisone (Tolperisone) Active ingredient concentration (mg): 150
Pharmacological effect
A muscle relaxant centrally acting. The mechanism of action is not fully understood. It has a membrane stabilizing, local anesthetic effect, inhibits the conduction of pulses in the primary afferent fibers and motor neurons, which leads to the blocking of spinal mono- and polysynaptic reflexes. It is also likely that it again inhibits the release of mediators by inhibiting the entry of Ca2 + into synapses. In the brainstem, it removes the relief of arousal along the reticulospinal pathway. Enhances peripheral blood flow regardless of the influence of the central nervous system. The weak spasmolytic and adrenoceptor blocking effect of tolperisone plays a role in the development of this effect.
Pharmacokinetics
AbsorptionAfter ingestion, tolperisone is well absorbed from the gastrointestinal tract. Cmax is achieved in 0.5-1 hours. Bioavailability is about 20%. Metabolism and elimination Tolperisone is metabolized in the liver and kidneys. Pharmacological activity of metabolites is unknown. Excreted in the urine as metabolites (more than 99%).
Indications
encephalopathy, vascular spasms in the brain, ischemic stroke, myasthenia nerve genesis, multiple sclerosis, pain syndromes in osteochondrosis (including Lyumbago), radiculitis, osteoarthritis deforming formation of hemorrhoids, renal colic, cholelithiasis.
Contraindications
The drug Mydocalm is contraindicated in the following cases: with myasthenia; in case of hypersensitivity to lidocaine, if injections are given, or to tolperisone; newborn babies up to 3 months.
Precautionary measures
Do not exceed recommended doses.
Use during pregnancy and lactation
In view of the lack of data on the use during pregnancy and during breastfeeding, the prescription of the drug Mydocalm is not recommended during these periods.
Dosage and administration
Adults: Usually starting with 50 mg 2-3 times a day, gradually increasing the dose to 150 mg 2-3 times a day.For children: For children aged 1 to 6 years, Mydocalm is administered orally at a daily dose of 5 mg / kg (in 3 doses per day); at the age of 7-14 years - in a daily dose of 24 mg / kg (in 3 doses during the day). A coated tablet should be rubbed if the child is not able to swallow it. For children, only 50 mg coated pills are allowed.
Side effects
Muscle weakness, headache, low blood pressure, nausea, vomiting, feeling of abdominal discomfort. With a decrease in dose side effects usually pass. In rare cases, an allergic reaction occurs (pruritus, erythema, urticaria, angioedema, anaphylactic shock, bronchospasm).
Overdose
Data overdose drug Mydocalm has been reported. There is no specific antidote. In case of overdose, gastric lavage and symptomatic therapy are recommended.
Interaction with other drugs
Data on the interaction that limits the use of the drug Mydocalm is not available. Although tolperisone has an effect on the central nervous system, the drug does not cause a sedative effect, so it can be used in combination with sedatives, hypnotics and drugs containing ethanol. Does not affect the effect of ethanol on the CNS. the simultaneous use of Mydocalm enhances the effect of niflumic acid, therefore, if necessary, the use of this combination may require a reduction in the dose of niflumic acid. Means for general anesthesia, peri feric muscle relaxants, psychotropic drugs, clonidine enhance the effect of tolperisone.
special instructions
It is necessary to use the drug strictly following the recommendations of the attending physician in order to avoid complications. Impact on the ability to drive vehicles and control mechanisms No studies have been conducted, but for many years of practice the use of information about the effect of Mydocalm on patients' ability to perform work requiring increased attention and psychomotor reactions is not there is.